ADMET, absorption, distribution, metabolism and excretion ­ toxicity in pharmacokinetics; AMP, antimicrobial peptide; AMR, antimicrobial resistance; ATCC, ATCC cell collection; Antibiotic; BAM, ß-barrel assembly machinery; CC50, cytotoxic concentration to kill 50% of cells; CD, circular dichroism; CFU, colony forming unit; CLSI, clinical and laboratory standards institute; CMS, colistin methane sulfonate; DMPC, 1,2-dimyristoyl-sn-glycero-3-phosphocholine; ESKAPE, acronym encompassing six bacterial pathogens (often carrying antibiotic resistance): Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp; FDA, U. S. Food and Drug Administration; HABP, hospital acquired bacterial pneumonia; HDP, host-defense peptide; HEK293, human embryonic kidney 293 cells; HK-2, human kidney 2 cells (proximal tubular cell line); HepG2, human hepatocellular carcinoma cell line; Hpg, 4-hydroxy-phenyl glycine; ITC, isothermal titration calorimetry; KPC, Klebsiella pneumoniae metallo-ß-lactamase C resistant; LPS, lipopolysaccharide; LptA, lipopolysaccharide transport protein A; LptC, lipopolysaccharide transport protein C; LptD, lipopolysaccharide transport protein D; MDR, multidrug-resistant; MH-I, Müller-Hinton broth I; MH-II, Müller-Hinton broth II (cation adjusted); MIC, minimal inhibitory concentration; MRSA, methicilline-resistant S. aureus; MSSA, methicilline-sensitive S. aureus; MoA, mechanism (mode) of action; NDM-1, New Delhi metallo-ß-lactamase resistant; NOAEL, no adverse effect level; ODL, odilorhabdin; OMPTA (outer membrane targeting antibiotic); OMPTA, outer membrane targeting antibiotic; Omp, outer membrane protein; PBMC, peripheral mononuclear blood cell; PBP, penicillin-binding protein; PBS, phosphate-buffered saline; PK, pharmacokinetics; POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; POPG, 2-oleoyl-1-palmitoyl-sn-glycero-3-phospho-(1-glycerol); PrAMPs, polyproline antimicrobial peptides; RBC, red blood cell; SAR, structure-activity relationship; SPR, surface plasmon resonance; SPase I, signal peptidase I; VABP, ventilator associated bacterial pneumonia; VIM-1, beta-lactamase 2 (K. pneumoniae); VISA, vancomycin-intermediate S. aureus; VRE, vancomycin-resistant enterococcus; WHO, World Health Organization; WT, wild type; WTA, wall teichoic acid; XDR, extremely drug-resistant; antimicrobial peptide; antimicrobial resistance; bid, bis in die (two times a day); i.p., intraperitoneal; i.v., intravenous; lipopeptide; mITT population, minimal intend-to-treat population; peptide antibiotic; s.c., subcutaneous